CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
Standard
CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. / Eberhardt, Kirsten Alexandra; Jung, Verena; Knops, Elena; Heger, Eva; Wirtz, Maike; Steger, Gertrud; Kaiser, Rolf; Affeldt, Patrick; Holtick, Udo; Klein, Florian; Scheid, Christof; Di Cristanziano, Veronica.
In: BONE MARROW TRANSPL, Vol. 58, No. 6, 06.2023, p. 639-646.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
AU - Eberhardt, Kirsten Alexandra
AU - Jung, Verena
AU - Knops, Elena
AU - Heger, Eva
AU - Wirtz, Maike
AU - Steger, Gertrud
AU - Kaiser, Rolf
AU - Affeldt, Patrick
AU - Holtick, Udo
AU - Klein, Florian
AU - Scheid, Christof
AU - Di Cristanziano, Veronica
N1 - © 2023. The Author(s).
PY - 2023/6
Y1 - 2023/6
N2 - Cytomegalovirus (CMV) represents one of the most common infectious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, a common diagnostic test used to stratify the risk for CMV infection in allo-HSCT recipients is the qualitative CMV serology of donor and recipient. A positive serostatus of the recipient is the most important risk factor for CMV reactivation and associated with reduced overall survival post-transplantation (TX). Direct and indirect effects of CMV are involved in the poorer survival outcome. The present study investigated if the quantitative interpretation of anti-CMV IgG before allo-HSCT might serve as a novel parameter for the identification of patients at risk for CMV reactivation and worse outcome post-TX. For this purpose, a cohort of 440 allo-HSCT recipients over a period of 10 years was retrospectively analyzed. Our findings indicated that patients with high CMV IgG pre-allo-HSCT had a higher risk to develop CMV reactivation, including clinically relevant infections, and a worse prognosis 36 months post-allo-HSCT as compared to recipients with low CMV IgG values. In the letermovir (LMV) era, this group of patients might benefit from a closer CMV monitoring, and hence, earlier intervention if needed, especially after discontinuation of prophylaxis.
AB - Cytomegalovirus (CMV) represents one of the most common infectious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, a common diagnostic test used to stratify the risk for CMV infection in allo-HSCT recipients is the qualitative CMV serology of donor and recipient. A positive serostatus of the recipient is the most important risk factor for CMV reactivation and associated with reduced overall survival post-transplantation (TX). Direct and indirect effects of CMV are involved in the poorer survival outcome. The present study investigated if the quantitative interpretation of anti-CMV IgG before allo-HSCT might serve as a novel parameter for the identification of patients at risk for CMV reactivation and worse outcome post-TX. For this purpose, a cohort of 440 allo-HSCT recipients over a period of 10 years was retrospectively analyzed. Our findings indicated that patients with high CMV IgG pre-allo-HSCT had a higher risk to develop CMV reactivation, including clinically relevant infections, and a worse prognosis 36 months post-allo-HSCT as compared to recipients with low CMV IgG values. In the letermovir (LMV) era, this group of patients might benefit from a closer CMV monitoring, and hence, earlier intervention if needed, especially after discontinuation of prophylaxis.
KW - Humans
KW - Retrospective Studies
KW - Transplantation, Homologous/adverse effects
KW - Cytomegalovirus Infections
KW - Hematopoietic Stem Cell Transplantation/adverse effects
KW - Cytomegalovirus/physiology
KW - Antibodies, Viral
KW - Immunoglobulin G
U2 - 10.1038/s41409-023-01944-2
DO - 10.1038/s41409-023-01944-2
M3 - SCORING: Journal article
C2 - 36869190
VL - 58
SP - 639
EP - 646
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 6
ER -